Association of pancreatic fat content with type II diabetes mellitus

C. Nadarajah, G. Fananapazir, E. Cui, J. Gichoya, N. Thayalan, M. Asare-Sawiri, C. O. Menias, K. Sandrasegaran

Research output: Contribution to journalArticle

Abstract

AIM: To determine the association between regional fat content in the pancreas and the presence or absence of type II diabetes mellitus (T2DM), the value of regional pancreatic fat quantification in identifying patients at risk of T2DM, and whether pancreatic fat content is associated with glycaemic control in T2DM. MATERIALS AND METHODS: A retrospective survey of a radiology database identified 45 patients with T2DM, and 81 “at risk for T2DM” patients who developed diabetes, between 0.6 and 3.7 years after magnetic resonance imaging (MRI). A control group who did not develop diabetes during a 5-year follow-up and without known metabolic syndrome, liver, or pancreatic diseases were also identified. Fat content was measured by placing regions of interest (ROIs) on in-phase and out-of-phase chemical shift MRI images. Multiple clinical parameters including body mass index, cholesterol levels, blood pressure, glycated haemoglobin (HbA1c; in T2DM group) were collected. RESULTS: There was a significant difference between the T2DM and control groups for fat fraction in the pancreatic head (p=0.043), body (p=0.015), and tail (p=0.001), but not liver (p=0.107). On regression analysis, only the fat fraction within the pancreatic tail was significantly different between control group and “at risk” for T2DM group (p=0.007). A pancreatic tail fat content of >10% had a sensitivity of 45.5% and specificity of 81.3% for predicting development of T2DM within 4 years. Pancreatic fat content was not associated with glycaemic control. CONCLUSIONS: Increased fat in the pancreatic tail may identify patients at risk for T2DM.

Original languageEnglish (US)
JournalClinical Radiology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Type 2 Diabetes Mellitus
Fats
Control Groups
Magnetic Resonance Imaging
Pancreatic Diseases
Glycosylated Hemoglobin A
Radiology
Liver Diseases
Pancreas
Body Mass Index
Cholesterol
Regression Analysis
Databases
Blood Pressure
Sensitivity and Specificity
Liver

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Nadarajah, C., Fananapazir, G., Cui, E., Gichoya, J., Thayalan, N., Asare-Sawiri, M., ... Sandrasegaran, K. (Accepted/In press). Association of pancreatic fat content with type II diabetes mellitus. Clinical Radiology. https://doi.org/10.1016/j.crad.2019.05.027

Association of pancreatic fat content with type II diabetes mellitus. / Nadarajah, C.; Fananapazir, G.; Cui, E.; Gichoya, J.; Thayalan, N.; Asare-Sawiri, M.; Menias, C. O.; Sandrasegaran, K.

In: Clinical Radiology, 01.01.2019.

Research output: Contribution to journalArticle

Nadarajah, C, Fananapazir, G, Cui, E, Gichoya, J, Thayalan, N, Asare-Sawiri, M, Menias, CO & Sandrasegaran, K 2019, 'Association of pancreatic fat content with type II diabetes mellitus', Clinical Radiology. https://doi.org/10.1016/j.crad.2019.05.027
Nadarajah C, Fananapazir G, Cui E, Gichoya J, Thayalan N, Asare-Sawiri M et al. Association of pancreatic fat content with type II diabetes mellitus. Clinical Radiology. 2019 Jan 1. https://doi.org/10.1016/j.crad.2019.05.027
Nadarajah, C. ; Fananapazir, G. ; Cui, E. ; Gichoya, J. ; Thayalan, N. ; Asare-Sawiri, M. ; Menias, C. O. ; Sandrasegaran, K. / Association of pancreatic fat content with type II diabetes mellitus. In: Clinical Radiology. 2019.
@article{a973c2b12c304d2798b284d9f8c5c31a,
title = "Association of pancreatic fat content with type II diabetes mellitus",
abstract = "AIM: To determine the association between regional fat content in the pancreas and the presence or absence of type II diabetes mellitus (T2DM), the value of regional pancreatic fat quantification in identifying patients at risk of T2DM, and whether pancreatic fat content is associated with glycaemic control in T2DM. MATERIALS AND METHODS: A retrospective survey of a radiology database identified 45 patients with T2DM, and 81 “at risk for T2DM” patients who developed diabetes, between 0.6 and 3.7 years after magnetic resonance imaging (MRI). A control group who did not develop diabetes during a 5-year follow-up and without known metabolic syndrome, liver, or pancreatic diseases were also identified. Fat content was measured by placing regions of interest (ROIs) on in-phase and out-of-phase chemical shift MRI images. Multiple clinical parameters including body mass index, cholesterol levels, blood pressure, glycated haemoglobin (HbA1c; in T2DM group) were collected. RESULTS: There was a significant difference between the T2DM and control groups for fat fraction in the pancreatic head (p=0.043), body (p=0.015), and tail (p=0.001), but not liver (p=0.107). On regression analysis, only the fat fraction within the pancreatic tail was significantly different between control group and “at risk” for T2DM group (p=0.007). A pancreatic tail fat content of >10{\%} had a sensitivity of 45.5{\%} and specificity of 81.3{\%} for predicting development of T2DM within 4 years. Pancreatic fat content was not associated with glycaemic control. CONCLUSIONS: Increased fat in the pancreatic tail may identify patients at risk for T2DM.",
author = "C. Nadarajah and G. Fananapazir and E. Cui and J. Gichoya and N. Thayalan and M. Asare-Sawiri and Menias, {C. O.} and K. Sandrasegaran",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.crad.2019.05.027",
language = "English (US)",
journal = "Clinical Radiology",
issn = "0009-9260",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Association of pancreatic fat content with type II diabetes mellitus

AU - Nadarajah, C.

AU - Fananapazir, G.

AU - Cui, E.

AU - Gichoya, J.

AU - Thayalan, N.

AU - Asare-Sawiri, M.

AU - Menias, C. O.

AU - Sandrasegaran, K.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - AIM: To determine the association between regional fat content in the pancreas and the presence or absence of type II diabetes mellitus (T2DM), the value of regional pancreatic fat quantification in identifying patients at risk of T2DM, and whether pancreatic fat content is associated with glycaemic control in T2DM. MATERIALS AND METHODS: A retrospective survey of a radiology database identified 45 patients with T2DM, and 81 “at risk for T2DM” patients who developed diabetes, between 0.6 and 3.7 years after magnetic resonance imaging (MRI). A control group who did not develop diabetes during a 5-year follow-up and without known metabolic syndrome, liver, or pancreatic diseases were also identified. Fat content was measured by placing regions of interest (ROIs) on in-phase and out-of-phase chemical shift MRI images. Multiple clinical parameters including body mass index, cholesterol levels, blood pressure, glycated haemoglobin (HbA1c; in T2DM group) were collected. RESULTS: There was a significant difference between the T2DM and control groups for fat fraction in the pancreatic head (p=0.043), body (p=0.015), and tail (p=0.001), but not liver (p=0.107). On regression analysis, only the fat fraction within the pancreatic tail was significantly different between control group and “at risk” for T2DM group (p=0.007). A pancreatic tail fat content of >10% had a sensitivity of 45.5% and specificity of 81.3% for predicting development of T2DM within 4 years. Pancreatic fat content was not associated with glycaemic control. CONCLUSIONS: Increased fat in the pancreatic tail may identify patients at risk for T2DM.

AB - AIM: To determine the association between regional fat content in the pancreas and the presence or absence of type II diabetes mellitus (T2DM), the value of regional pancreatic fat quantification in identifying patients at risk of T2DM, and whether pancreatic fat content is associated with glycaemic control in T2DM. MATERIALS AND METHODS: A retrospective survey of a radiology database identified 45 patients with T2DM, and 81 “at risk for T2DM” patients who developed diabetes, between 0.6 and 3.7 years after magnetic resonance imaging (MRI). A control group who did not develop diabetes during a 5-year follow-up and without known metabolic syndrome, liver, or pancreatic diseases were also identified. Fat content was measured by placing regions of interest (ROIs) on in-phase and out-of-phase chemical shift MRI images. Multiple clinical parameters including body mass index, cholesterol levels, blood pressure, glycated haemoglobin (HbA1c; in T2DM group) were collected. RESULTS: There was a significant difference between the T2DM and control groups for fat fraction in the pancreatic head (p=0.043), body (p=0.015), and tail (p=0.001), but not liver (p=0.107). On regression analysis, only the fat fraction within the pancreatic tail was significantly different between control group and “at risk” for T2DM group (p=0.007). A pancreatic tail fat content of >10% had a sensitivity of 45.5% and specificity of 81.3% for predicting development of T2DM within 4 years. Pancreatic fat content was not associated with glycaemic control. CONCLUSIONS: Increased fat in the pancreatic tail may identify patients at risk for T2DM.

UR - http://www.scopus.com/inward/record.url?scp=85075467735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075467735&partnerID=8YFLogxK

U2 - 10.1016/j.crad.2019.05.027

DO - 10.1016/j.crad.2019.05.027

M3 - Article

C2 - 31711639

AN - SCOPUS:85075467735

JO - Clinical Radiology

JF - Clinical Radiology

SN - 0009-9260

ER -